HC Wainwright set a $10.00 target price on Aduro BioTech (NASDAQ:ADRO) in a research note issued to investors on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other research analysts have also issued reports about the company. Oppenheimer set a $15.00 price objective on Aduro BioTech and gave the stock a buy rating in a research report on Monday, December 11th. Canaccord Genuity set a $30.00 price objective on Aduro BioTech and gave the stock a buy rating in a research report on Thursday, December 14th. William Blair reissued an outperform rating on shares of Aduro BioTech in a research report on Monday, October 2nd. Finally, BidaskClub lowered Aduro BioTech from a hold rating to a sell rating in a research report on Saturday, December 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Aduro BioTech currently has a consensus rating of Buy and a consensus target price of $17.71.
Aduro BioTech (ADRO) opened at $8.05 on Tuesday. Aduro BioTech has a twelve month low of $6.01 and a twelve month high of $14.05.
In related news, EVP Dirk G. Brockstedt sold 4,123 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $8.04, for a total value of $33,148.92. Following the completion of the sale, the executive vice president now directly owns 77,841 shares of the company’s stock, valued at approximately $625,841.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jennifer Lew sold 6,600 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $9.46, for a total value of $62,436.00. Following the completion of the sale, the vice president now directly owns 68,938 shares of the company’s stock, valued at $652,153.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 316,365 shares of company stock valued at $2,858,183. Corporate insiders own 6.60% of the company’s stock.
A number of institutional investors have recently modified their holdings of ADRO. Legal & General Group Plc increased its position in Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 1,043 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Aduro BioTech in the 3rd quarter valued at about $127,000. SG Americas Securities LLC bought a new stake in Aduro BioTech in the 3rd quarter valued at about $167,000. Trexquant Investment LP bought a new stake in Aduro BioTech in the 3rd quarter valued at about $175,000. Finally, Voya Investment Management LLC increased its position in Aduro BioTech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 2,515 shares in the last quarter. 45.19% of the stock is owned by institutional investors and hedge funds.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
What are top analysts saying about Aduro BioTech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro BioTech and related companies.